Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)
Status:
Withdrawn
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, dose-rising study evaluating the safety, tolerability, and
preliminary efficacy of three concentrations of SOR007 ointment (0.15%, 1.0%, and 2.0%)
applied topically once per week for four weeks to the ectocervix of subjects with high grade
cervical intraepithelial neoplasia (CIN).